Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by Accountprinceon Jul 22, 2021 12:17pm
176 Views
Post# 33588007

RE:Anyone know if Western Ivey

RE:Anyone know if Western Ivey Can't answer for MBA but Seto is a CPA (formerly CMA in 1999 per Spectral) now.  And yes ethics courses are required from time to time when you hold a CPA in addition to acting ethically per professional rules while you are a CPA.  Not sure of IIROC requires ethics training or adherence as part of working at an investment bank.

Speaking of which I am perplexed about Paradigm.  Facts - you put forward market research in April 2019 ascribing a value of $2.00 per share, then revise that to $4.00 per share in Feb 2020, then do a private placement of shares for the same company at $0.60 per share in June 2020, then revise your ascribed value to $3.20 per share after that (can't remember the date) and now do a bought deal at $0.40 per share.  No further revision as far as I know so $3.20 still stands.  I always thought that when an investment dealer did research and tells the public what they think the company is worth then that's actually what they think it's worth.  Is that wrong?

If not wrong then are you misleading the public with your researched value and potentially having them buy based on that value only to lead an equity issue at 15% or less of your published value?  I am asking as I am not aware of any rule that absolves this situation.  Perhaps there is if someone knows.
<< Previous
Bullboard Posts
Next >>